CONCERT PHARMACEUTICALS INC's ticker is CNCE and the CUSIP is 206022105. A total of 94 filers reported holding CONCERT PHARMACEUTICALS INC in Q1 2019. The put-call ratio across all filers is 0.72 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $2,924 | -99.9% | 500,605 | -22.1% | 0.00% | -33.3% |
| Q3 2022 | $4,305,000 | +10.2% | 642,605 | -30.8% | 0.01% | +20.0% |
| Q2 2022 | $3,908,000 | +172.0% | 928,184 | +117.7% | 0.01% | +150.0% |
| Q1 2022 | $1,437,000 | -20.8% | 426,305 | -26.0% | 0.00% | 0.0% |
| Q4 2021 | $1,814,000 | -25.8% | 575,805 | -23.0% | 0.00% | -33.3% |
| Q3 2021 | $2,444,000 | -41.7% | 747,400 | -24.7% | 0.00% | -40.0% |
| Q2 2021 | $4,190,000 | -9.1% | 993,000 | +7.6% | 0.01% | -16.7% |
| Q1 2021 | $4,607,000 | -36.7% | 923,224 | +60.3% | 0.01% | -25.0% |
| Q4 2020 | $7,282,000 | +18.3% | 576,100 | -8.1% | 0.01% | +33.3% |
| Q3 2020 | $6,154,000 | -4.0% | 626,700 | -2.7% | 0.01% | 0.0% |
| Q2 2020 | $6,408,000 | +17.9% | 644,000 | +4.7% | 0.01% | +20.0% |
| Q1 2020 | $5,437,000 | -7.1% | 615,000 | -3.1% | 0.01% | +25.0% |
| Q4 2019 | $5,852,000 | +61.1% | 634,400 | +2.7% | 0.00% | +33.3% |
| Q3 2019 | $3,633,000 | -50.9% | 617,790 | +0.3% | 0.00% | -57.1% |
| Q2 2019 | $7,392,000 | -13.0% | 616,000 | -12.5% | 0.01% | -12.5% |
| Q1 2019 | $8,492,000 | -1.7% | 703,600 | +2.2% | 0.01% | -11.1% |
| Q4 2018 | $8,641,000 | -20.3% | 688,500 | -5.7% | 0.01% | -18.2% |
| Q3 2018 | $10,839,000 | -49.6% | 730,400 | -33.6% | 0.01% | -8.3% |
| Q2 2018 | $21,523,000 | +90.2% | 1,100,600 | +122.7% | 0.01% | 0.0% |
| Q1 2018 | $11,317,000 | +22.1% | 494,200 | +38.0% | 0.01% | +20.0% |
| Q4 2017 | $9,267,000 | +65.4% | 358,200 | -5.7% | 0.01% | +42.9% |
| Q3 2017 | $5,604,000 | +5.4% | 379,900 | -0.3% | 0.01% | 0.0% |
| Q2 2017 | $5,316,000 | -14.6% | 381,100 | +4.5% | 0.01% | -22.2% |
| Q1 2017 | $6,223,000 | +38.8% | 364,800 | -16.3% | 0.01% | +28.6% |
| Q4 2016 | $4,484,000 | +37.1% | 435,800 | +34.8% | 0.01% | +16.7% |
| Q3 2016 | $3,270,000 | +80.6% | 323,404 | +100.5% | 0.01% | +100.0% |
| Q2 2016 | $1,811,000 | -21.6% | 161,300 | -4.7% | 0.00% | -25.0% |
| Q1 2016 | $2,311,000 | -35.5% | 169,200 | -10.4% | 0.00% | -50.0% |
| Q4 2015 | $3,583,000 | +690.9% | 188,889 | +531.7% | 0.01% | +700.0% |
| Q1 2015 | $453,000 | – | 29,900 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 4,420,349 | $25,814,838 | 3.96% |
| Parkman Healthcare Partners LLC | 1,203,484 | $7,028,347 | 1.87% |
| SPHERA FUNDS MANAGEMENT LTD. | 1,002,783 | $5,856,253 | 1.26% |
| TANG CAPITAL MANAGEMENT LLC | 1,150,000 | $6,716,000 | 0.98% |
| BVF INC/IL | 3,629,000 | $21,193,360 | 0.89% |
| Nantahala Capital Management | 1,732,388 | $10,117,146 | 0.66% |
| AWM Investment Company, Inc. | 666,661 | $3,893,300 | 0.56% |
| INGALLS & SNYDER LLC | 1,295,833 | $7,568 | 0.41% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 200,800 | $1,172,672 | 0.36% |
| Kensington Investment Counsel, LLC | 58,599 | $342,218 | 0.27% |